170 related articles for article (PubMed ID: 14756678)
1. An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats.
Arakawa K; Ishihara T; Aoto M; Inamasu M; Kitamura K; Saito A
Clin Exp Pharmacol Physiol; 2004; 31(1-2):8-13. PubMed ID: 14756678
[TBL] [Abstract][Full Text] [Related]
2. Cardiac hypertrophy caused by peroxisome proliferator- activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling.
Sena S; Rasmussen IR; Wende AR; McQueen AP; Theobald HA; Wilde N; Pereira RO; Litwin SE; Berger JP; Abel ED
Endocrinology; 2007 Dec; 148(12):6047-53. PubMed ID: 17823261
[TBL] [Abstract][Full Text] [Related]
3. Arterial vasodilators, cardiac volume load, and cardiac hypertrophy in normotensive rats.
Tsoporis J; Yuan BX; Leenen FH
Am J Physiol; 1989 Mar; 256(3 Pt 2):H876-80. PubMed ID: 2522286
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo.
Asakawa M; Takano H; Nagai T; Uozumi H; Hasegawa H; Kubota N; Saito T; Masuda Y; Kadowaki T; Komuro I
Circulation; 2002 Mar; 105(10):1240-6. PubMed ID: 11889020
[TBL] [Abstract][Full Text] [Related]
5. The renin-angiotensin system and volume overload-induced cardiac hypertrophy in rats. Effects of angiotensin converting enzyme inhibitor versus angiotensin II receptor blocker.
Ruzicka M; Yuan B; Harmsen E; Leenen FH
Circulation; 1993 Mar; 87(3):921-30. PubMed ID: 8443912
[TBL] [Abstract][Full Text] [Related]
6. Norepinephrine-induced cardiac hypertrophy of the cat heart.
Marino TA; Cassidy M; Marino DR; Carson NL; Houser S
Anat Rec; 1991 Apr; 229(4):505-10. PubMed ID: 1828654
[TBL] [Abstract][Full Text] [Related]
7. Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats.
Ruzicka M; Yuan B; Leenen FH
Circulation; 1994 Jul; 90(1):484-91. PubMed ID: 8026035
[TBL] [Abstract][Full Text] [Related]
8. Effects of arterial vasodilators on cardiac hypertrophy and sympathetic activity in rats.
Tsoporis J; Leenen FH
Hypertension; 1988 Apr; 11(4):376-86. PubMed ID: 2895737
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic and metabolic activities of propionyl-L-carnitine in rats with pressure-overload cardiac hypertrophy.
Yang XP; Samaja M; English E; Benatti P; Tarantola M; Cardace G; Motterlini R; Micheletti R; Bianchi G
J Cardiovasc Pharmacol; 1992 Jul; 20(1):88-98. PubMed ID: 1383636
[TBL] [Abstract][Full Text] [Related]
10. Wall stress and patterns of hypertrophy in the human left ventricle.
Grossman W; Jones D; McLaurin LP
J Clin Invest; 1975 Jul; 56(1):56-64. PubMed ID: 124746
[TBL] [Abstract][Full Text] [Related]
11. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
Rose M; Balakumar P; Singh M
Pharmacology; 2007; 80(2-3):177-84. PubMed ID: 17570955
[TBL] [Abstract][Full Text] [Related]
12. Cardiac hypertrophy due to pressure and volume overload: distinctly different biological phenomena?
Rossi MA; Carillo SV
Int J Cardiol; 1991 May; 31(2):133-41. PubMed ID: 1831183
[TBL] [Abstract][Full Text] [Related]
13. Time-course of changes in cardiac hypertrophy and pressor mechanisms in two-kidney, one clip hypertensive rats during treatment with minoxidil, enalapril or after uninephrectomy.
Leenen FH; Prowse S
J Hypertens; 1987 Feb; 5(1):73-83. PubMed ID: 2884253
[TBL] [Abstract][Full Text] [Related]
14. Cellular basis of wall remodeling in long-term pressure overload-induced right ventricular hypertrophy in rats.
Olivetti G; Ricci R; Lagrasta C; Maniga E; Sonnenblick EH; Anversa P
Circ Res; 1988 Sep; 63(3):648-57. PubMed ID: 2970334
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Iglarz M; Touyz RM; Viel EC; Paradis P; Amiri F; Diep QN; Schiffrin EL
Hypertension; 2003 Oct; 42(4):737-43. PubMed ID: 12860836
[TBL] [Abstract][Full Text] [Related]
16. Diastolic characteristics and cardiac energetics of isolated hearts exposed to volume and pressure overload.
Friberg P
Cardiovasc Res; 1988 May; 22(5):329-39. PubMed ID: 2973372
[TBL] [Abstract][Full Text] [Related]
17. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats.
Olivetti G; Quaini F; Lagrasta C; Ricci R; Tiberti G; Capasso JM; Anversa P
Am J Pathol; 1992 Jul; 141(1):227-39. PubMed ID: 1385927
[TBL] [Abstract][Full Text] [Related]
18. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats.
Barone FC; Coatney RW; Chandra S; Sarkar SK; Nelson AH; Contino LC; Brooks DP; Campbell WG; Ohlstein EH; Willette RN
Cardiovasc Res; 2001 Jun; 50(3):525-37. PubMed ID: 11376628
[TBL] [Abstract][Full Text] [Related]
19. Morphometric analysis of collagen network and plasma perfused capillary bed in the myocardium of rats during evolution of cardiac hypertrophy.
Michel JB; Salzmann JL; Ossondo Nlom M; Bruneval P; Barres D; Camilleri JP
Basic Res Cardiol; 1986; 81(2):142-54. PubMed ID: 2427067
[TBL] [Abstract][Full Text] [Related]
20. Epigallocatechin-3 gallate prevents cardiac hypertrophy induced by pressure overload in rats.
Hao J; Kim CH; Ha TS; Ahn HY
J Vet Sci; 2007 Jun; 8(2):121-9. PubMed ID: 17519564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
